BRD2 and lymphoma: This is consistent with previous findings that IBET preferentially targets BRD4 over BRD2 and BRD3, and that lymphoma Raji cells stably expressing a dominant negative BRD4 displayed near identical global effects on gene expression to those treated with the BET inhibitor JQ1 (Decker et al., 2017; Filippakopoulos et al., 2010).